Type 2 diabetes patients on semaglutide had 15% fewer fractures than those on other weight loss drug
For years, doctors have worried that rapid weight loss could come with an unwanted side effect: weaker bones and a greater risk of fractures.
But a new study is offering encouraging news for people taking Ozempic and Wegovy.
Researchers have found that semaglutide, the active ingredient in the blockbuster medications, may actually help protect bone health in adults with Type 2 diabetes. The findings suggest patients taking the drug were less likely to suffer bone fractures than people using other popular weight-loss treatments.
The research was presented at ENDO 2026, the Endocrine Society’s annual meeting held in Chicago from June 13 to June 16.
Researchers found a lower fracture risk
The study examined health records from more than 59,000 adults living with Type 2 diabetes. Researchers analyzed 26,324 patients who were prescribed semaglutide. They compared those patients with 33,555 adults taking other weight loss medications.
Investigators recorded 794 fractures among semaglutide users, compared with 1,045 fractures in the comparison group.
After accounting for differences between the groups, researchers found that patients taking semaglutide were about 15% less likely to experience a bone fracture.
The findings surprised some experts because weight loss has traditionally been associated with concerns about declining bone density, especially in older adults.
Instead, semaglutide users not only lost more weight than those taking competing medications, but they also appeared to maintain stronger bones.
Why the findings matter
Bone fractures can have serious consequences, particularly for older adults.
A broken hip, spine or wrist can affect mobility, independence and overall quality of life. Recovery can also be lengthy and expensive, making fracture prevention a major public health concern.
The possibility that semaglutide could reduce fracture risk while helping people manage their weight and blood sugar levels has sparked interest among researchers and physicians alike.
A former endocrinology fellow at Stanford University Medical Center who led the study, said the results represent an important first step in understanding how these medications affect bone health.
He noted that fractures can be painful, costly and especially disruptive as people age. The researchers hope the study encourages healthcare providers to pay closer attention to bone health as part of weight loss treatment programs.
Ozempic and Wegovy continue to attract attention
Semaglutide has become one of the most talked-about medications in recent years.
Sold under the brand names Ozempic and Wegovy, the drug belongs to a class of medications known as GLP-1 receptor agonists.
Ozempic is approved to help manage blood sugar levels in adults with Type 2 diabetes, while Wegovy is prescribed for chronic weight management.
The medications work by mimicking hormones that regulate appetite and blood sugar, helping patients feel fuller for longer periods and consume fewer calories. Their popularity has skyrocketed as studies continue to reveal benefits beyond weight loss.
Researchers have previously linked GLP-1 drugs to improvements in cardiovascular health and blood sugar control. Now, the possibility that they may also support bone health is adding another dimension to the conversation.
Questions remain about long term effects
Although the findings are promising, researchers caution that more work is needed.
The study was observational, meaning it looked at medical records rather than assigning patients to different treatments in a controlled clinical trial.
As a result, scientists cannot yet say with certainty that semaglutide directly caused the reduction in fractures.
Future research will need to explore why semaglutide users appeared to have stronger bones and whether the protective effects extend to people without Type 2 diabetes.
Researchers are also interested in understanding how long the benefits may last and whether factors such as age, sex or existing bone conditions influence the results.
A promising development for millions of patients
For now, the findings offer reassurance to many patients and doctors who have wondered whether dramatic weight loss could come at the expense of bone health.
Instead of weakening bones, semaglutide may provide an added layer of protection for people already managing the challenges of Type 2 diabetes.
With millions of Americans using Ozempic and Wegovy, the discovery could have significant implications for how healthcare providers approach long term treatment and wellness.
While scientists continue to investigate the connection, the latest research suggests that patients taking these medications may be gaining more than improved blood sugar control and weight loss.
They may also be building a stronger foundation for their future health.